Trials / Unknown
UnknownNCT05114603
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation
An Open-label, Multicenter Phase II Clinical Study to Evaluate Safety, Efficacy and PK of HLX208 for Advanced Melanoma With BRAF V600 Mutation
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Shanghai Henlius Biotech · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for advanced melanoma with BRAF V600 mutation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HLX208 | level 1:600mg po Bid level 2:900mg po Bid |
Timeline
- Start date
- 2022-03-21
- Primary completion
- 2023-08-30
- Completion
- 2024-08-30
- First posted
- 2021-11-10
- Last updated
- 2022-05-03
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05114603. Inclusion in this directory is not an endorsement.